KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Finished Goods: 2013-2025

Historic Finished Goods for Supernus Pharmaceuticals (SUPN) over the last 11 years, with Sep 2025 value amounting to $16.7 million.

  • Supernus Pharmaceuticals' Finished Goods fell 31.28% to $16.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.7 million, marking a year-over-year decrease of 31.28%. This contributed to the annual value of $16.4 million for FY2024, which is 45.05% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Finished Goods stood at $16.7 million for Q3 2025, which was down 16.28% from $20.0 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Finished Goods registered a high of $46.7 million during Q3 2022, and its lowest value of $12.5 million during Q3 2021.
  • Its 3-year average for Finished Goods is $27.2 million, with a median of $28.7 million in 2024.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Finished Goods soared by 272.49% in 2022 and then plummeted by 45.05% in 2024.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Finished Goods stood at $32.9 million in 2021, then rose by 6.34% to $35.0 million in 2022, then declined by 14.54% to $29.9 million in 2023, then slumped by 45.05% to $16.4 million in 2024, then tumbled by 31.28% to $16.7 million in 2025.
  • Its Finished Goods was $16.7 million in Q3 2025, compared to $20.0 million in Q2 2025 and $22.1 million in Q1 2025.